Strata Skin Sciences (NASDAQ:SSKN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Strata Skin Sciences (NASDAQ:SSKN) to a sell rating in a report published on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Strata Skin Sciences Trading Up 2.1%

SSKN opened at $1.93 on Friday. The stock has a 50-day moving average of $1.88 and a 200 day moving average of $2.21. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 49.58. Strata Skin Sciences has a 12 month low of $1.38 and a 12 month high of $3.86. The firm has a market cap of $8.05 million, a P/E ratio of -0.68 and a beta of 0.50.

Strata Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings data on Wednesday, August 13th. The medical device company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.33). The company had revenue of $7.70 million during the quarter, compared to the consensus estimate of $8.56 million. Strata Skin Sciences had a negative net margin of 35.13% and a negative return on equity of 266.94%. As a group, research analysts forecast that Strata Skin Sciences will post -1.05 EPS for the current year.

About Strata Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.